Conference abstractPublished 26 Nov 2018
A systems pharmacology approach to higher order drug combinations in prostate cancer
Systems Biology Ireland- UCD, Ireland
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Healthy aging in men coincides with regular screening of their prostate as malignancies may develop at any time. Malignancies in prostate start as local disease but aggressive tumour development might lead to a non-localized metastatic disease state (mPCa). The unmet clinical need remains i.e. to eradicate mPCa and return men to a healthier. Methodology: We used evolutionary modelling to estimate the number of drugs necessary to eradicate mPCa. Then we carried out a perturbation study in which we treated mPCa models with six drugs in single and all double drug combinations. Changes to the proteome were quantified using targeted proteomics and reverse protein arrays. This analysis identified a number of proteins and signal transduction pathways to be targeted in a triple drug combination. Commercially available inhibitors had uncertain binding specificity against the target and we used structure-based drug design to assess their specificity. Following our analysis, triple drug combinations were tested in a mPCa model. Results: Due to the tumour burden and heterogeneity in mPCa, more than two drugs are required to obtain a reduction in tumour mass. Most likely triple combination therapy will be necessary to overcome the emergence of drug resistance and return men to healthier state. Identifying ways in which tumours block the action of two drugs is a way of prioritizing drug targets for triple combinations. Conclusions: The combined approach of in silico modelling and systems pharmacology resulted in a promising new drug combination to treat mPCa. Recent Publications: 1. A Root and H A Ebhardt (2018) A two-drug combination simulation study for metastatic castrate resistant prostate cancer. The Prostate 78(15):1196-1200. 2. H A Ebhardt (2018) Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. NPJ Syst. Biol. Appl. 4:26.
Subjects
Biochemistry & BiotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Proteomics & Bioinformatics
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “H Alexander Ebhardt”
